and 3.7 × 10 6 /kg from day 10 to day 12 after mobilization chemotherapy (P Ͻ 0.001). To obtain sufficient For blood progenitor cell (BPC) mobilization, standardcell numbers for engraftment a median of 2 (range, 1-3) dose VIP chemotherapy consisting of etoposide, ifosfammobilization chemotherapy cycles were needed in MM ide and cisplatin has previously shown effective tumor compared to 1 (range, 1-10) in solid tumor or lymreduction in solid tumor patients and sufficient progeniphoma patients, with a median of 5 (range, 2-8) leutor cell mobilization for autologous blood cell transplankaphereses in MM compared to 1 (range, 1-10) (P Ͻ tation. Mobilization chemotherapy regimens in multiple 0.05). Taken together, we found that for patients with myeloma (MM) predominantly consist of melphalan or MM, VP16 and ifosfamide efficiently and predictably cyclophosphamide that induce marked cytopenia and mobilizes progenitor cells into the PB with у3 × 10 6 /kg considerable variability of progenitor cell collection. We CD34 + cells collected after one to two mobilization studied whether in MM (n = 13), BPCs were efficiently chemotherapy cycles. High-dose chemotherapy with autologous blood cell transanalyzed. Before chemotherapy (day 0), on day 7 after plantation (BCT) has become widely used as potentially chemotherapy and on days of leukapheresis (day 9-14), curative treatment for solid tumors, lymphomas and acute leukocyte numbers, mononuclear cells (MNCs), CD34 + leukemia.
) and identical dosing of G-CSF were
High-dose chemotherapy with autologous blood cell transanalyzed. Before chemotherapy (day 0), on day 7 after plantation (BCT) has become widely used as potentially chemotherapy and on days of leukapheresis (day 9-14), curative treatment for solid tumors, lymphomas and acute leukocyte numbers, mononuclear cells (MNCs), CD34 + leukemia. 1 Blood progenitor cells (BPC) collected after cells and coexpression of lineage markers were anacytokine or combined chemotherapy and cytokine mobilizlyzed. Median blood leukocyte numbers were 28 100/l ation, are used to reduce hematopoietic damage. As an (range, 19 600-40 400) on day 10 in myeloma patients alternative source to bone marrow, BPCs show several and progressively declined over the next 4 days. In conadvantages including relative ease of collection, more rapid trast, in solid tumor and lymphoma patients leukocyte hematopoietic recovery after high-dose treatment [2] [3] [4] [5] and numbers constantly increased from a median of reduced tumor cell contamination. 6 12 400/l (range, 6000-22 000) to 30 000/l (range, At our institution, patients with solid tumors or lym-16 300-63 300) between day 10 and day 13 after chemophoma are treated with standard-dose induction chemotherapy. Similar to leukocyte counts, median MNC therapy to mobilize sufficient numbers of BPCs. 7, 8 numbers decreased in myeloma patients with successive Although in multiple myeloma (MM) a number of mobilizleukaphereses, but steadily increased in solid tumor and ation chemotherapy protocols have been reported to be uselymphoma patients over the same period. CD34
+ cell ful, kinetics of BPC mobilization are less well docunumbers in the blood peaked between day 9 and 11 mented. 9-11 Adequate and predictable BPC mobilization, (median: 40/l) in myeloma patients and then declined.
however, is necessary to ensure safe engraftment after highIn the solid tumor and lymphoma group, median CD34 + dose therapy and when purging strategies are to follow stem counts in the blood peaked on day 12 after mobilization cell harvests. chemotherapy (median: 100/l). The median CD34
+
We used a standard-dose combination chemotherapy yield per leukapheresis in the myeloma group was before initiating stem cell harvest as a means of in vivo 2.2 × 10 6 /kg (range, 1.5-4.7) on day 10, and fell steadily purging as well as for stem cell mobilization. In this trial, to 0.95 × 10 6 /kg on day 12, whereas in solid tumor/NHL we studied the mobilization kinetics of BPCs in MM, in patients median CD34
+ cell yields remained between 3.5 solid tumor and in non-Hodgkin's lymphoma (NHL) patients after chemotherapy and G-CSF treatment. BPC Harvesting was performed by continuous flow leukapherhad a diagnosis of non-Hodgkin's lymphoma (NHL), 16 esis using a CS-3000 Plus blood cell separator (Baxter, had solid tumors (11 breast cancer, three small-cell lung Munich, Germany) following the second cycle of chemocancer, two germ cell tumor patients) and 13, MM. Four therapy when the absolute white blood count (WBC) healthy donors were also included. According to the Kiel exceeded 5 ϫ 10 9 /l for all patient groups. Blood volume classification there were 10 centrocytic-centroblastic and processed per run was 6 l at a flow rate of 50-70 ml/min. two centrocytic NHL. Ten of the NHL patients had stage IV Apheresis was continued until у1 ϫ 10 6 CD34 + cells/kg disease (10/12). Thirteen of the 45 patients had undergone for solid tumor patients and у3 ϫ 10 6 /kg in NHL and MM extensive pretreatment (Ͼsix chemotherapy cycles), 15 patients had been obtained. The target cell dose in healthy moderate pretreatment (Ͻsix chemotherapy cycles) and 17 donors was 3.5 ϫ 10 6 CD34 + cells/kg bw. In patients who had received no prior chemotherapy. Patient characteristics failed to collect the target number of CD34 + cells within are listed in Table 1 . The majority were treated in first or five aphereses a second mobilization chemotherapy was second relapse (70%) and 30% in first remission. Cytoperformed. On days of stem cell collection, each apheresis reductive chemotherapy was given prior to BPC harvest product was analyzed for CD34 + cell expression by flow and transplantation. Solid tumor and NHL patients were cytometry (FACScan, Becton Dickinson). The white blood treated with two cycles of standard-dose VIP chemotherapy count (WBC) was measured using a Coulter counter consisting of etoposide (VP16) (500 mg/m 2 ), ifosfamide (4 (Coulter, Krefeld, Germany). Mononuclear cells (MNC) g/m 2 ) and cisplatin (50 mg/m 2 ) as this regimen has prewere defined in percentage after subtraction of neutrophils, viously been shown to be active in a variety of tumors. 7, 8 bands, eosinophils and basophils. The WBC, MNCs, Granulocyte colony-stimulating factor (G-CSF, filgrastim, CD34 + cells and coexpression of lineage markers (by flow Neupogen; Amgen, Munich, Germany) was started 24 h cytometry) were analyzed in the peripheral blood on day 0 after the end of each chemotherapy cycle at daily sub-(before chemotherapy), on day 7 (after chemotherapy) and cutaneous (s.c.) injections of 5 g/kg body weight (bw).
on days of leukapheresis. A total of 230 peripheral blood Patients with MM received VI chemotherapy consisting of samples and 124 apheresis products were analyzed. etoposide (500 mg/m 2 ) and ifosfamide (4 g/m 2 ) followed by s.c. G-CSF (5 g/kg). As cisplatinum is not active in MM, it was omitted from the mobilization regimen.
12 HealImmunfluorescence staining thy donors received 24 g rhG-CSF/kg bw in two subcutaneous (s.c.) bolus administrations at 12 g/kg and Samples from peripheral blood (PB) and leukapheresis BPCs were collected beginning on day 4. On days of leuwere analyzed by dual-color immunfluorescence as kapheresis rhG-CSF was administered 3-7 h before apherdescribed by Siena et al. 14 by multiplying the number of CD34 + cells by the white Culture assays blood count. MNC 1 ϫ 10 5 from PB and apheresis samples were culFor analysis of CD34 + cell content, the MNC fraction tured in 0.9% methylcellulose supplemented with Iscove's from leukapheresis products was incubated with anti-CD34 modified Dulbecco's medium (IMDM) and 30% fetal bov-PE-conjugated MoAB and analyzed for CD34 + cells by ine serum (FBS; Paesel, Frankfurt, Germany). Semisolid flow cytometry as described above. The number of CD34 + cultures were performed in duplicates, stimulated with cells in each BPC product was determined by multiplying recombinant human erythropoietin (1 U/ml, Cilag, Sulzthe total nucleated cell number in the harvest product by bach, Germany), IL-3 (100 ng/ml, Genzyme) and GM-CSF the percentage of CD34 + cells.
(100 ng/ml, Genzyme). Colonies Ͼ50 cells were scored as A FACScan analyzer (Becton Dickinson) was used and CFU-GM, BFU-E and CFU-GEMM after 14 days with an data acquisition was performed with FACScan Lysis II inverted microscope. software. For analysis, a total of 50 000-100 000 cells were acquired. Table 2) . Prior irradiation and bone marrow that after two VI induction chemotherapy cycles all 13 MM patients showed a median reduction in total serum protein involvement reduced CD34 + collection efficiency and more than halved CD34
+ cell yields in MM compared to lymof 15% (range, 5-35%), immunoglobin (IgG, IgA or IgM) levels of 40% (range, 10-55%), and lactic dehydrogenase phoma patients (Table 2 ). Due to limited patient numbers, however, differences in CD34 + cells for bone marrow (LDH) of 25% (range, 13-40%). Bone marrow biopsies available in four MM patients before and after the VI mobiinvolvement and irradiation showed a 3-4-fold reduction in myeloma compared to NHL patients but did not reach lization chemotherapy showed a reduction of 83% (range, 50-100%) in tumor infiltration.
statistical significance ( Table 2 ). The groups were well balanced for age and Karnofsky performance status (Table 1) 
. Prior treatment in terms of
Peripheral blood (PB) cell counts the numbers of chemotherapy cycles was comparable in NHL and MM (Table 1 ). All (12/12) NHL and 11/13 MM Leukapheresis was started in all patients when blood leukocyte levels exceeded 5 ϫ 10 9 /l. In solid tumor and NHL patients had received prior chemotherapy (Table 1) . Seven NHL patients had VACOP-B pretreatment over 12 weeks patients, white blood cell (WBC) counts were considerably lower at the beginning of apheresis (median on day 10: with a total dose of 2.25 g/m 2 cyclophosphamide, 300 mg/m 2 doxorubicin, 8.4 mg/m 2 vincristine, 750 mg/m 2 eto-12.4 ϫ 10 9 /l) compared to MM patients (median, 28.1 ϫ 10 9 /l) (P Ͻ 0.05). Following G-CSF, solid tumor/ poside and 54 mg/m 2 bleomycin. Five NHL patients had been treated with four cycles of CHOP receiving a total NHL patients increased their WBC further, but the WBC in MM remained almost stable (Figure 1a) . Myeloma patients dose of 3 g/m 2 cyclophosphamide, 200 mg/m 2 doxorubicin and 5.6 mg/m 2 vincristine. Three SCLC and two germ cell showed an earlier rise in WBC beyond 10 ϫ 10 9 /l on day 9 (median, 13.5 ϫ 10 9 /l) (not shown). Similar to the WBC, cancer patients had received two cycles of a cisplatinumcontaining regimen (total dose 100 mg/m 2 ). Eleven out of MNCs in the peripheral blood rose steadily during the observation period in solid tumor/NHL patients but fell in 28 patients with high-risk breast cancer (у10 positive lymph nodes, receptor negative) had not had prior chemo-MM after the peak level on day 10 (Figure 1b ). Platelet counts did not limit leukapheresis (threshold level therapy. Pretreatment in eight of 13 MM patients had consisted of melphalan, with two having received prolonged Ͻ20 ϫ 10 9 /l) in any patient. (Ͼ12 months) and six moderate (Ͼ6 and Ͻ12 months) treatment. Two MM patients had received two cycles of CD34 + cells in the PB standard-dose VAD, one two cycles of fludarabine and two only had high-dose dexamethasone (40 mg/m 2 ) treatment.
Baseline circulating CD34 + cells were detected at a frequency of 1-2/l (range, 0.6-10) in the peripheral blood. Spinal radiation therapy had been performed in four MM patients and one with NHL (Table 2) .
After chemotherapy and G-CSF administration the CD34
+ population increased about 50-fold to an average of 40-Following mobilization with chemotherapy plus G-CSF or G-CSF treatment alone, BPC collections were started at 100/l in all patients. However, CD34 + cell numbers in the PB showed lower levels in MM (P = 0.08) compared to a median WBC of 22 ϫ 10 9 /l (range, 7.3-56.3 ϫ 10 9 /l). BPCs were harvested for a median of 5 (range, 2-8) leusolid tumor/NHL and healthy donors especially after day 11 of mobilization therapy (Figure 1c ). kapheresis days in MM, whereas a median of 1 (range, 1-10) was sufficient in solid tumor and NHL patients (P Ͻ 0.05). In half of the MM patients (6/13) a median of 2 CD34 + cells in apheresis products (range, 1-3) mobilization chemotherapy cycles were needed for collecting у3 ϫ 10 6 CD34 + cells/kg, compared Median CD34 + yields in the apheresis products were more than twice as high in solid tumor/NHL patients and healthy with three NHL patients (3/12) ( Table 1) , all extensively P value within MM and NHL patients. c P value between patient groups MM and NHL. NA = not applicable for statistical evaluation because of sample size in non-irradiated patient group; NV = non-valid for statistical evaluation due to limited patient size in melphalan group Ͻ12 months; NC = non-comparable to NHL group. donors than in MM (P Ͻ 0.001). On successive days of patients (Table 1) . Only one MM patient (1/13), but seven NHL patients (7/12), had sufficient CD34 + cells after apheresis, CD34
+ cell numbers decreased in MM patients and harvest results deteriorated (Figure 1d ). In solid tumor CD34 + separation (у3 ϫ 10 6 /kg) and could be transplanted with selected cells (Table 1 ). In the other patients, unseparand NHL patients, CD34
+ cell numbers showed a continuous plateau over a 3-day period (Figure 1d ). Similar levels ated cells were added to the CD34 + cell fraction. Thus, highest numbers of leukocytes, MNC and CD34
+ of CD34
+ cells were observed in the blood of healthy donors over a 2-day period (day 4, 4.4 ϫ 10 6 /kg; day 5, cells in PB and apheresis products were achieved on day 9 and 10 in MM which then decreased considerably, 5.2 ϫ 10 6 /kg). whereas in solid tumors/NHL increasing numbers of all parameters and stable leukapheresis results were obtained Apheresis results over 3 consecutive days (Figure 1a-d) . In healthy donors, 24 g G-CSF applied twice daily (2 × 12 g) subcutaneThe CD34
+ count was significantly lower in the leukapheresis products of MM patients (median, 2.7 ϫ 10 6 /kg; range, ously allowed sufficient cell numbers for allogeneic transplantation (target cell number: 3.5 ϫ 10 6 CD34 + cells/kg 0.3-14) compared to those with solid tumors/NHL (6.7 ϫ 10 6 /kg; range, 0.3-17) and in healthy donors bw) in one leukapheresis. (11.3 ϫ 10 6 /kg; range, 7.6-15) (P Ͻ 0.001). In NHL with bone marrow involvement (10/12) and in MM patients (11/13), CD34
+ immunoaffinity column separClonogenic assays ation was performed. In two MM patients with CD34
+ harvest yields of less than 0.5 ϫ 10 6 /kg bw no column separNo colony growth was detected in samples under steadystate conditions. After VIP and G-CSF administration the ation was initiated. The median purity of CD34 + cells was 61%, varying between 31% and 85%. No significant differtotal number of colonies in each sample paralleled the CD34 + cell peak in peripheral blood and leukapheresis proence in CD34
+ purity was observed between NHL and MM samples. The median CD34 + recovery after positive selecducts. There was a rise in colony-forming units (CFU) during the time of leukapheresis with peak levels on day 10 tion was 25% (range, 6.9-67.8) in all patients, and with 31% (range, 20.5-67.8) in NHL significantly higher than in solid tumor and NHL patients. Peak total colony numbers in solid tumors/NHL patients were 121 (median with 13.3% (range, 6.9-37.2) in MM patients (P = 0.02). : 40/ml (3-2128) increasing on day 12 to 100/ml (10-430), 100/ml (10-435), 97/ml (9-418) and 98/ml (8-420), respectively). Median numbers in MM on day 10 were 39/ml (4-144), 40/ml (4-147), 36/ml (4-130) and 36/ml (4-120) and decreased on day 12 to 31/ml (3-57), 19/ml (1-58), 23/ml (1-54), 25/ml (1-48) for CD34
+ cells coexpressing CD38, HLA-DR, CD33 and CD71, respectively. However, both solid tumors/NHL and MM patients showed similar percentages of CD34 subpopulations during apheresis revealing an increasing number of CD34
+ cells coexpressing lineageassociated markers. No CD34 + /CD19 + cells in the PB were apparent in solid tumor/NHL and in MM. In healthy donors, considerably higher percentages of lineage negative cells were detected in the PB (Figure 2 ). CD34
+ cells with a more primitive phenotype appeared earlier whereas progenitor cells with a more lineage-committed phenotype were found on later days of apheresis (Figure 2) .
Prediction of apheresis yields
To assess whether measurement of CD34 + cells in the peripheral blood allows the estimation of progenitor cell yields of apheresis products, we analyzed corresponding peripheral blood and apheresis products. The number of CD34 + cell/l in the blood was found to correlate closely with CD34 + progenitor yields in apheresis products (r = 0.83) rather than with MNC numbers in the blood (r = 0.63) or harvest products (r = 0.1). Thus, CD34 + cell numbers in days 10-13. In ST/NHL patients, WBCs were lower at the beginning of apheresis and increased on further days whereas in MM, WBCs peaked the peripheral blood allowed a reliable prediction of harvest on day 10 and remained almost stable on following days of aphereses (a).
results, whereas the WBC and MNCs were less useful and Similar to the WBC, MNCs rose steadily in ST/NHL but fell in MM after inferior predictors of expected CD34 + cell yields in blood day 10 (b). CD34 + cell numbers in the PB showed lower levels in MM or apheresis products. Analysis of CD34 + cell numbers in compared to ST/NHL, in particular after day 11 of mobilization therapy (c). CD34 + yields in apheresis products were more than twice as high from the peripheral blood and apheresis products indicated that ST/NHL compared to MM patients (d).
a concentration of 60/l CD34 + cells in the blood predicted a leukapheresis harvest of 1.5 ϫ 10 6 in MM patients, but of 3 ϫ 10 6 /kg in solid tumors/NHL with a single leukaphertumors/NHL and MM, respectively. There was no signifiesis ( Figure 4 ). In cases of CD34 + cell levels greater than cant difference in colony types within our patient groups. 60/l, threshold CD34 + cell yields of Ͼ1, Ͼ2 and Ͼ3 ϫ 10 6 /kg were obtained in 100%, 97% and 78% of patients, respectively (Table 3) . A smaller proportion of Surface markers of CD34 + cells in blood MM patients than solid tumors/NHL patients obtained these CD38, HLA-DR, CD33 were used as hematopoietic lineage target quantities in harvest products when 60/l CD34 + markers and CD71, as specific for the human transferrin cells were detected in the blood (Table 3) . receptor, for determining early erythroid cells. CD19, + cells with a more primitive phenotype were found to appear earlier in the PB whereas progenitor cells with a more lineagecommitted phenotype were seen on later days of apheresis.
Discussion
donors confirmed previous reports that in chemo-naive patients similar CD34 + numbers are obtained with G-CSF alone as compared to minimally pretreated patients with With conventional chemotherapy, fewer than 10% of MM patients achieve complete remission, and the median surchemotherapy and G-CSF. 20 This illustrates that less treatment is of benefit for BPC mobilization and that minimizvival is less than 3 years.
2 High-dose therapy and autologous transplantation improve response rates and overall suring prior chemotherapy is desirable, especially in MM. Whether in heavily pretreated patients, high-dose twice vival. 10, 11, 15 Favorable results with response rates of 40-50% and an overall survival of 30-70 months have daily G-CSF (24 g/kg bw) after mobilization chemotherapy rather than a further mobilization cycle, might especially been observed in patients with limited prior chemotherapy and chemo-sensitive disease. 15, 16 Although improve BPC release awaits future testing. For the early rise in WBC in MM, the most likely expla-BCT has been performed in MM, BPC yields are comparatively low, regardless of the amount of pretreatment. 17 In nation is that myeloma patients did not receive platinum as part of their mobilization chemotherapy which has failed addition, the number of aphereses to achieve threshold levels for safe engraftment defined as between 2-5 ϫ 10 6 /kg to show beneficial therapeutic effects in myeloma 12 but induces marrow toxicity and inhibits progenitor mobiliz-CD34 + cells is relatively high, with up to five harvests needed. [17] [18] [19] Previous analysis stresses prior chemotherapy, ation. 21 At the beginning of leukapheresis (day 10), peripheral blood CD34 + numbers were only 1.1-fold lower in MM marrow infiltration and irradiation as major factors adversely affecting collection efficiency. 12, 16, [20] [21] [22] [23] [24] In particompared to NHL patients, and then decreased subsequently 1.4-, and 3.3-fold, respectively. In leukapheresis cular, heavy pretreatment has been indicated, with a reduction of 0.2 ϫ 10 6 /kg CD34 + cells with each chemoproducts, however, the difference between NHL and MM patients was more pronounced with a 1.6-, 2.6-and 3.8-therapy cycle 23 and an inability to mobilize sufficient BPCs in 72% patients after more than 24 months of chemofold difference in CD34 + cell numbers on days 10, 11 and 12, respectively. Similarly, after positive selection progenitherapy. 22 We have shown that tumor cytoreduction and sufficient tor cell numbers (2.1-fold) and CD34 + recovery (2.3-fold) were more than double in patients with NHL compared to progenitor mobilization is feasible in MM patients after G-CSF supported VP16 and ifosfamide chemotherapy. Howthose with MM. The reason for the discrepancy between the CD34 + cell numbers in the PB at the beginning of aphever, in MM significantly lower stem cell yields as determined by CD34 + cell numbers were found both in blood eresis but low numbers in harvest yields is unclear. Perhaps the elevated plasma viscosity in myeloma interferes with and leukapheresis products compared to patients with solid tumors and NHL. As the number of pretreatment chemothe gradient during apheresis and/or Ig-coated CD34 + cells might be less efficiently separated. therapy cycles and the degree of bone marrow infiltration in NHL and MM patients were comparable, other factors CD34 + cell analysis is commonly used to predict leukapheresis yields and to determine mobilization profiles. 23 may account for inferior apheresis yields. Melphalan has in previous studies shown to result in permanent stem cell Others have suggested alternatives to CD34 + cell determination and use a rapidly rising leukocyte count as the standamage, faster stem cell exhaustion and impaired progenitor mobilization. 22 From our analysis, patients who had dard method to start progenitor collection. 25 In our study, CD34 + cells in the peripheral blood correlated closely with received Ͻsix cycles of chemotherapy prior to mobilization and no melphalan achieved significantly higher CD34 + cell the CD34 + cell yield in corresponding leukapheresis products, whilst WBCs, MNCs and CFUs were inferior predicyields. Bone marrow infiltration and irradiation also reduced progenitor numbers although this did not reach tors. Our results suggest that this parameter is valuable for the timing of leukapheresis. In solid tumor and NHL statistical significance. Our mobilization data in healthy patients, levels of 60/l CD34 + cells indicated that target 
CD34
+ cell numbers in harvest products could be obtained, tumor/NHL and MM patients lineage-negative cells, as early during apheresis and deteriorated with CD34 + cell
